Edwards Lifesciences Corp
Edwards Lifesciences (EW) insider Wayne Markowitz sold 1,240 shares at $91.47 each, totaling $113,422.80. Over the past year, insiders have sold 37 times with no buys. The company's P/E ratio is 52.17, higher than industry median. GuruFocus values the stock as fairly valued with a GF Value of $94.99.
Edwards Lifesciences CVP Daveen Chopra sold 31,800 shares for $2.89m after exercising options. Shares were sold at $90.99-$91.76 each. Chopra now holds 44,324 shares. Edwards Lifesciences reported Q2 earnings of $0.78 EPS and $1.74B revenue, raising full-year outlook. Analysts updated price targets and ratings.
Chopra Daveen (CVP, TMTT, Surgical & IHFM) sold 31,800 shares of Edwards Lifesciences Corp (EW) at an average of $91.02 ($90.99–$91.76, $2.89M total) across 2 trades on 2026-08-26.
Over the past 7 days, alphai's AI scored 4 news stories mentioning EW (Edwards Lifesciences Corp). Coverage has been balanced: 1 bullish, 2 neutral, and 1 bearish.
Recent EW coverage spans financial news, earnings and insider activity.
In the last 30 days, EW insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($3.1M). The most active reporter was Markowitz Wayne, CVP, JAPAC, with 2 filings. 20% of those filings were made under pre-arranged Rule 10b5-1 plans.
The sale adds to a pattern of insider divestment, suggesting limited upside sentiment.
Insider sale modestly offsets bullish earnings surprise; overall sentiment remains positive.
The insider sale may signal reduced confidence or liquidity need, potentially pressuring the stock short-term.
Small insider sale may signal modest confidence shift but unlikely to move price materially.
Small insider sale unlikely to move price; may slightly increase supply perception.
alphai scores every news story that mentions EW with an AI model for sentiment and relevance, and aggregates insider trades from Edwards Lifesciences Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Edwards Lifesciences (EW) insider Wayne Markowitz sold 1,240 shares at $91.47 each, totaling $113,422.80. Over the past year, insiders have sold 37 times with no buys. The company's P/E ratio is 52.17, higher than industry median. GuruFocus values the stock as fairly valued with a GF Value of $94.99.
1 min readEdwards Lifesciences CVP Daveen Chopra sold 31,800 shares for $2.89m after exercising options. Shares were sold at $90.99-$91.76 each. Chopra now holds 44,324 shares. Edwards Lifesciences reported Q2 earnings of $0.78 EPS and $1.74B revenue, raising full-year outlook. Analysts updated price targets and ratings.
2 min readChopra Daveen (CVP, TMTT, Surgical & IHFM) sold 31,800 shares of Edwards Lifesciences Corp (EW) at an average of $91.02 ($90.99–$91.76, $2.89M total) across 2 trades on 2026-08-26.
1 min readMarkowitz Wayne (CVP, JAPAC) sold 1,240 shares of Edwards Lifesciences Corp (EW) at $91.46 ($0.11M total) on 2026-08-26.
1 min readEdwards Lifesciences (EW) officer Wayne Markowitz filed a Rule 144 notice to sell 1,240 shares, valued at $113,417. The shares stem from restricted stock lapses. Markowitz previously sold 9,775 shares in the past three months. EW has 576.4M shares outstanding.
1 min readEdwards Lifesciences (EW) officer Daveen Chopra plans to sell up to 31,800 shares, valued at $2.9M, on 08/26/2026, via Charles Schwab. The sale is linked to an employee stock option exercise.
1 min readEdwards Lifesciences (EW) reports growth in its TMTT and TAVR businesses, with Q2 2026 sales up 10.5% and 44.8% respectively. The company faces risks from currency fluctuations and competition. EW's stock gained 16.9% over the past year, outperforming its industry. Earnings yield is 3.3%, and the company expects 2026 gross margin near the lower end of its range.
2 min readEdwards Lifesciences (EW) reported Q2 2026 revenue up 13.6% to $1.74B and adjusted EPS up 16.4% to 78 cents. TAVR sales rose 10.5% (constant currency) and 2026 guidance was raised; TMTT sales grew 44.8% (constant currency) with 2026 guidance lifted. The article cites an average analyst price target of $101.78 and a forward P/E of 28.78.
6 min readCiti analyst Joanne Wuensch reiterated a Buy rating on Edwards Lifesciences (EW) and set a $110 price target. The article notes other analyst views including J.P. Morgan Buy and Canaccord Genuity Hold. It cites EW quarterly revenue of $1.74B and net profit of $241.9M for the quarter ended June 30, versus $1.53B revenue and $329.8M net profit a year earlier.
2 min readEdwards Lifesciences (EW) has a $53.9B market cap and modestly lagged the S&P 500 over 52 weeks. After Q2 2026 results on Jul. 23, adjusted EPS was $0.78 vs $0.67, and 2026 revenue guidance was raised to $6.6B-$6.9B. Analysts expect 2026 adjusted EPS of $3. Piper Sandler lifted its target to $101.
3 min read
